SIPULEUCEL-T (*cont.*)

ADULT — Treatment of metastatic hormone-refractory prostate cancer in patients who are symptomatic or minimally symptomatic. Administer a total of 3 doses at 2-week intervals.
PEDS — Not approved in children.
FORMS — Infusion, premixed in preservative-free LR. Greater than 50 million autologous CD54+ cells activated with PAP-GM-CSF (250 mL).
NOTES — No pregnancy or lactation data. Not indicated for use in women. Premedication with oral acetaminophen and diphenhydramine is recommended to minimize infusion reactions.

THALIDOMIDE (*Thalomid*) ▶Plasma ♀X ◀? $$$$$

WARNING — Pregnancy category X. Has caused severe, life-threatening human birth defects. Available only through special restricted distribution program. Prescribers and pharmacists must be registered in this program in order to prescribe or dispense. During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.
ADULT — Chemotherapy doses vary by indication. Multiple myeloma with dexamethasone. Erythema nodosum leprosum: 100 to 400 mg PO at bedtime. Use low end of dose range for initial episodes and if wt less than 50 kg.
PEDS — Not approved in children.
UNAPPROVED ADULT — Graft vs. host reactions after bone marrow transplant, Crohn's disease, Waldenstrom's macroglobulinemia, Langerhans cell histiocytosis, AIDS-related aphthous stomatitis.
UNAPPROVED PEDS — Clinical trials show beneficial effects when combined with dexamethasone in multiple myeloma.
FORMS — Trade only: Caps 50, 100, 150, 200 mg.

ONCOLOGY: Mitotic Inhibitors

CABAZITAXEL (*Jevtana*) ▶L ♀–D ◀–

WARNING — Neutropenia, febrile neutropenia: Neutropenic deaths have been reported. Severe hypersensitivity reactions can occur. Mortality related to diarrhea has been reported. Renal failure, including cases with fatal outcomes, has been reported. Patients older than 65 yo were more likely to experience fatal outcomes not related to disease. Should not be given to patients with hepatic impairment. QTc interval prolongation.
ADULT — Indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. 25 mg/m^2 administered IV q 3 weeks in combination with oral prednisone 10 mg administered daily throughout treatment.
PEDS — Not indicated in children.
FORMS — Single-use vial 60 mg/1.5 mL, supplied with diluent (5.7 mL).
NOTES — Premedication regimen required 30 minutes before each dose: Antihistamine, corticosteroid (dexamethasone 8 mg or equivalent steroid) and H2 antagonist.

DOCETAXEL (*Docefrez, Taxotere*) ▶L ♀D ◀– $ varies by therapy

WARNING — Severe hypersensitivity with anaphylaxis, bone marrow suppression, fluid retention, neutropenia, rash, erythema of the extremities, nail hypo- or hyperpigmentation, hepatotoxicity, treatment-related mortality, paresthesia/dysesthesia, asthenia, fertility impairment, alopecia. Alopecia may be irreversible. Instruct patients to report promptly fever, sore throat, or signs of local infection. Treatment with docetaxel products may cause alcohol intoxication.
ADULT — Chemotherapy doses vary by indication. Breast cancer, non-small-cell lung cancer. Hormone-refractory, metastatic prostate cancer, advanced gastric adenocarcinoma with cisplatin and fluorouracil, squamous cell carcinoma of the head and neck with cisplatin and fluorouracil.
PEDS — Not approved in children.
UNAPPROVED ADULT — Gastric cancer, melanoma, non-Hodgkin's lymphoma ovarian cancer, pancreatic cancer, prostate cancer, small-cell lung cancer, soft-tissue sarcoma, urothelial cancer, adjuvant and neoadjuvant breast cancer.
FORMS — IV concentrate: 20, 80, 140, 160 mg vials.
NOTES — Reliable contraception is recommended. Monitor CBCs and LFTs. CYP3A4 inhibitors or substrates may lead to significant increases in blood concentrations.

ERIBULIN (*Halaven*) ▶feces – ♀D ◀–

WARNING — Dose reduction may be required in patients with hepatic impairment or renal impairment.
ADULT — Metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
PEDS — Not approved in children.
FORMS — 1 mg/2 mL IV solution for injection.
NOTES — Dose is 1.4 mg/m^2 on days 1 and 8 q 21 days.

IXABEPILONE (*Ixempra*) ▶L ♀D ◀– $ varies by therapy

WARNING — Contraindicated in patients with AST or ALT greater than 2.5 ULN or bilirubin more than 1 times ULN upper limit of normal or higher.

(cont.)